CERVICAL CANCER AND HUMAN PAPILLOMAVIRUS COINFECTION: EPIDEMIOLOGY, RISK FACTORS, AND PREVENTION

Authors

  • No’monjonova Muhlisaxon,Mirzayeva Saidaxon Abdusalomovna Medical Student, General Medicine Program Andijan Branch of Kokand University Andijan, Uzbekistan,Professor, Department of Microbiology, Virology and Immunology Andijan Branch of Kokand University Andijan, Uzbekistan Author

Keywords:

cervical cancer, human papillomavirus, HPV, HPV coinfection, high-risk HPV, cervical intraepithelial neoplasia, epidemiology, risk factors, HPV vaccination, cervical screening, HPV DNA testing, molecular diagnostics, women’s health, cancer prevention, public health.

Abstract

Cervical cancer remains one of the most common malignancies affecting women worldwide and continues to represent a major public health concern despite remarkable advances in vaccination and screening programs. Persistent infection with high-risk human papillomavirus (HPV) is recognized as the primary etiological factor responsible for cervical carcinogenesis. However, increasing evidence indicates that coinfection involving multiple HPV genotypes, together with various behavioral, immunological, and environmental risk factors, may influence viral persistence and disease progression. This review aimed to evaluate the current epidemiology of cervical cancer and HPV coinfection, analyze the principal risk factors associated with disease development, and summarize contemporary prevention strategies. A comprehensive narrative review of peer-reviewed literature was conducted using publications retrieved from PubMed, Scopus, Web of Science, Google Scholar, and reports from international health organizations. The reviewed evidence confirms that persistent high-risk HPV infection, particularly HPV-16 and HPV-18, remains the dominant cause of cervical cancer, while multiple HPV genotype coinfections may increase the risk of persistent infection and progression to cervical intraepithelial neoplasia in selected populations. Additional contributing factors include early sexual activity, multiple sexual partners, smoking, immunosuppression, HIV infection, long-term oral contraceptive use, and inadequate participation in cervical screening programs. The findings further demonstrate that prophylactic HPV vaccination, HPV DNA testing, liquid-based cytology, organized cervical screening, and public health education are highly effective in reducing cervical cancer incidence and mortality. Nevertheless, substantial inequalities in vaccine coverage and healthcare accessibility continue to contribute to the global disease burden. Future research should focus on the biological mechanisms of HPV coinfection, novel molecular biomarkers, and personalized preventive strategies to improve early diagnosis and optimize cervical cancer prevention worldwide.

References

1. World Health Organization. (2024). Cervical cancer. Geneva, Switzerland: World Health Organization.

2. World Health Organization. (2024). Human papillomavirus (HPV) and cervical cancer. Geneva, Switzerland: World Health Organization.

3. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249.

4. Arbyn, M., Weiderpass, E., Bruni, L., de Sanjosé, S., Saraiya, M., Ferlay, J., & Bray, F. (2020). Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis. The Lancet Global Health, 8(2), e191–e203.

5. Schiffman, M., Doorbar, J., Wentzensen, N., de Sanjosé, S., Fakhry, C., Monk, B. J., Stanley, M., & Franceschi, S. (2016). Carcinogenic human papillomavirus infection. Nature Reviews Disease Primers, 2, 16086.

6. Burd, E. M. (2016). Human papillomavirus and cervical cancer. Clinical Microbiology Reviews, 29(2), 371–393.

7. Bruni, L., Albero, G., Serrano, B., Mena, M., Gómez, D., Muñoz, J., et al. (2023). Human Papillomavirus and Related Diseases Report. ICO/IARC Information Centre on HPV and Cancer.

8. International Agency for Research on Cancer. (2022). WHO Classification of Female Genital Tumours (5th ed.). Lyon, France: IARC Press.

9. Cohen, P. A., Jhingran, A., Oaknin, A., & Denny, L. (2019). Cervical cancer. The Lancet, 393(10167), 169–182.

10. World Health Organization. (2020). Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem. Geneva, Switzerland: World Health Organization.

11. Bosch, F. X., Lorincz, A., Muñoz, N., Meijer, C. J. L. M., & Shah, K. V. (2002). The causal relation between human papillomavirus and cervical cancer. Journal of Clinical Pathology, 55(4), 244–265.

12. Muñoz, N., Bosch, F. X., de Sanjosé, S., Herrero, R., Castellsagué, X., Shah, K. V., et al. (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. The New England Journal of Medicine, 348(6), 518–527.

13. Garland, S. M., Kjaer, S. K., Muñoz, N., Block, S. L., Brown, D. R., DiNubile, M. J., et al. (2016). Impact and effectiveness of the quadrivalent human papillomavirus vaccine: A systematic review of 10 years of real-world experience. Clinical Infectious Diseases, 63(4), 519–527.

14. Crosbie, E. J., Einstein, M. H., Franceschi, S., & Kitchener, H. C. (2013). Human papillomavirus and cervical cancer. The Lancet, 382(9895), 889–899.

15. Canfell, K., Kim, J. J., Brisson, M., Keane, A., Simms, K. T., Caruana, M., et al. (2020). Mortality impact of achieving WHO cervical cancer elimination targets: A comparative modelling analysis. The Lancet, 395(10224), 591–603.

Downloads

Published

2026-06-09